BioLife Solutions Inc (NASDAQ:BLFS) CFO Greef Roderick De sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $16.53, for a total transaction of $165,300.00. Following the sale, the chief financial officer now owns 40,359 shares in the company, valued at approximately $667,134.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Greef Roderick De also recently made the following trade(s):
- On Wednesday, March 20th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $19.83, for a total transaction of $198,300.00.
- On Wednesday, February 20th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.23, for a total transaction of $172,300.00.
Shares of BLFS opened at $16.36 on Monday. BioLife Solutions Inc has a 52 week low of $6.92 and a 52 week high of $26.35. The company has a market cap of $305.15 million, a P/E ratio of 116.86 and a beta of 1.62.
A number of research analysts recently commented on BLFS shares. ValuEngine downgraded shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 27th. Zacks Investment Research downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, BidaskClub raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. BioLife Solutions currently has a consensus rating of “Buy” and a consensus target price of $17.75.
A number of institutional investors and hedge funds have recently made changes to their positions in BLFS. Bank of New York Mellon Corp purchased a new position in BioLife Solutions during the third quarter valued at approximately $835,000. BlackRock Inc. grew its position in BioLife Solutions by 199.8% in the third quarter. BlackRock Inc. now owns 153,610 shares of the medical equipment provider’s stock worth $2,688,000 after acquiring an additional 102,364 shares in the last quarter. GSA Capital Partners LLP bought a new stake in BioLife Solutions in the third quarter worth approximately $200,000. Renaissance Technologies LLC grew its position in BioLife Solutions by 106.8% in the third quarter. Renaissance Technologies LLC now owns 427,900 shares of the medical equipment provider’s stock worth $7,488,000 after acquiring an additional 221,000 shares in the last quarter. Finally, Jane Street Group LLC grew its position in BioLife Solutions by 43.9% in the third quarter. Jane Street Group LLC now owns 21,841 shares of the medical equipment provider’s stock worth $382,000 after acquiring an additional 6,660 shares in the last quarter. 40.71% of the stock is currently owned by hedge funds and other institutional investors.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
See Also: Mutual Funds
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.